Sign Out
Pharmacotherapeutic Group: Antibacterial.
Pharmacology: Antibiotic action: A third-generation cephalosporin, cefpodoxime proxetil is a bactericidal agent that inhibits cell wall synthesis. It's usually active against gram-positive aerobes such as S. aureus (including penicillinase-producing strains). S. saprophyticus, S. pneumonia, and S. pyrogenes, a gram-negative aerobes, such as E. coli, H. influenza (including beta-lactamase-producing strain), K. pneumoniae, M. catarrhalis, Neisseria gonorrhea (including penicillinase-producing strains), and P. mirabilis.
Pharmacokinetics: Cefpodoxime proxetil is de-esterified in the intestinal epithelium following oral administration, to release active cefpodoxime in the blood stream. Bioavailability is about 50% in fasting subjects and may be increased in the presence of food. Absorption is decreased in conditions for low gastric acidity. Plasma concentrations of about 1.5, 2.5 and 4.0 μg per mL have been achieved 2 to 3 hours after oral doses of 100, 200 and 400 mg cefpodoxime respectively. About 20 to 30% of cefpodoxime is bound to plasma proteins. The plasma half-life is about 2 to 3 hours and is prolonged in patients with impaired renal function. Cefpodoxime reaches therapeutic concentrations in the respiratory and genitourinary tracts and bile. It has been detected in low concentrations in breast milk. Cefpodoxime is excreted unchanged in the urine. It is removed by dialysis.
